John Lee, MD
Interventional Cardiology · Plano, TXNPI 1679764948
Payments from drug & device makers
Across 269 payments — averaging $35.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$3K
- Amgen$892
- Abiomed$817
- Medtronic$688
- Novartis$590
- Abbott$509
- plus $3K from 33 others
What the payments were for
- Travel & lodging$1,75618%
- Food & beverage$7,88982%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 22 | $2,781 |
| Amgen | 50 | $892 |
| Abiomed | 10 | $817 |
| Medtronic(2 entities) | 6 | $688 |
| Novartis | 28 | $590 |
| Abbott | 7 | $509 |
| Pfizer | 19 | $352 |
| AstraZeneca | 16 | $306 |
| Merck | 14 | $273 |
| E.r. Squibb & Sons, L.L.C. | 14 | $272 |
| Shockwave Medical, Inc | 3 | $264 |
| Johnson & Johnson | 13 | $232 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 14 | $193 |
| Biotronik Inc. | 1 | $157 |
| Kiniksa Pharmaceuticals, Ltd. | 6 | $150 |
| Heartflow, Inc. | 2 | $125 |
| Cardiva Medical, Inc. | 3 | $109 |
| Boehringer Ingelheim | 5 | $108 |
| Astellas Pharma US Inc | 5 | $98 |
| Novo Nordisk | 4 | $96 |
| Philips North America LLC | 3 | $84 |
| Kestra Medical Technology Services, Inc. | 2 | $68 |
| Alnylam Pharmaceuticals Inc. | 2 | $50 |
| Irhythm Technologies, Inc. | 2 | $49 |
| Lexicon Pharmaceuticals, Inc. | 2 | $48 |
| Davol Inc. | 2 | $46 |
| Medicomp Inc | 2 | $43 |
| Atricure, Inc. | 1 | $32 |
| Recor Medical Inc | 1 | $29 |
| GSK | 1 | $26 |
| BD | 1 | $26 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $23 |
| Cvrx, Inc. | 1 | $21 |
| Cordis US CORP. | 1 | $18 |
| Edwards Lifesciences | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $17 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
| Scpharmaceuticals Inc. | 1 | $16 |
| Chiesi USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JETSTREAM$1,070
- GENERAL VASCULAR ACCESS$862
- Impella$412
- Repatha$247
- ONYX FRONTIER$226
- LINQ II$211
- ELUVIA$205
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$161
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$160
- DRAGONFLY OPSTAR$159
- Orsiro Mission$157
- AVVIGO Guidance System$152
- FFRct$110
- CoreValve Evolut$109
- Micra$107
How this compares
$9,659 in reported general payments places this provider in the 45th percentile of 686 interventional cardiology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 475 | $513,294 |
| EntrestoSacubitril/Valsartan | 55 | $83,619 |
| XareltoRivaroxaban | 76 | $82,161 |
| JardianceEmpagliflozin | 54 | $68,662 |
| Repatha SureclickEvolocumab | 74 | $66,220 |
| BrilintaTicagrelor | 25 | $17,729 |
| FarxigaDapagliflozin Propanediol | 15 | $16,631 |
| Praluent PenAlirocumab | 27 | $14,581 |
| CorlanorIvabradine Hcl | 11 | $7,312 |
| Rosuvastatin Calcium | 517 | $6,482 |
| Ranolazine ErRanolazine | 77 | $5,880 |
| Metoprolol Succinate | 408 | $5,670 |
| Atorvastatin Calcium | 460 | $3,698 |
| Valsartan | 149 | $3,320 |
| Ezetimibe | 143 | $3,171 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $352 | $513,294475 claims |
| NovartisEntresto | $590 | $83,61955 claims |
| Johnson & JohnsonXarelto | $232 | $82,16176 claims |
| Boehringer IngelheimJardiance | $108 | $68,66254 claims |
| AstraZenecaBrilinta, Farxiga | $306 | $34,36040 claims |
| AmgenCorlanor | $892 | $7,31211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 686 interventional cardiology providers in Texas.
Other interventional cardiology in Plano
- Srinivasa PotluriPlano$5.1M
- Sameh SayfoPlano$2.5M
- Karim Al-AziziPlano$1.6M
- Molly SzerlipPlano$1.5M
- Vijay RamanathPlano$438K
- Robert StolerDallas$8.2M
- James ChoiDallas$5.2M
- Neal KleimanHouston$4.8M
- Juan GranadaHouston$4.3M
- Ira LieberKingwood$3.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.